Concepedia

Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial

Joaquín Hinojosa, Fernando Gomollón, Guillermo Bastida, José Luis Cabriada, Cristina Morales Saro, Daniel Ceballos, M. Peñate, M.À. Gassull

Alimentary Pharmacology & Therapeutics · 2007 · 95 citations · 24 references

DOIFull text

Open access

Abstract

Adalimumab may be an effective alternative in patients with luminal and/or fistulizing Crohn's disease who have lost response to or become intolerant of infliximab.

References

24

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.1K citations

, , +5

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

William R. Best, Jack M. Becktel, John W. Singleton et al. · PubMed · 1976 · 3.2K citations

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.1K citations · Full text

Development of a Crohn's Disease Activity Index

William R. Best, Jack M. Becktel, John W. Singleton et al. · Gastroenterology · 1976 · 3.1K citations

, , +2

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · New England Journal of Medicine · 1999 · 2.7K citations · Full text